All In Biotech

Drug Trial Radar · NCT07543796

Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled Phase IIb Study to Evaluate the Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 12, 2026

Primary completion

Dec 14, 2026

Study completion Apr 25, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IIa, multicenter ,randomized, double-blind, Double-Dummy, Active- and placebo-controlled study designed to evaluate the efficacy, safety and kinetic characteristics of TRD205 tablets for postoperative analgesia after unilateral hip arthroplasty

Conditions

  • Postoperative Analgesia After Unilateral Hip Arthroplasty

Interventions

  • TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 dosesDrug

    First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)

  • TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 dosesDrug

    First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)

  • TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 dosesDrug

    First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)

  • Celecoxib, oral; 400 mg initial dose, then 200 mg q12h; total 4 dosesDrug

    First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)

  • Matching placebo tablets and capsules, same dosing scheduleDrug

    First dose 2-4 hours before anesthesia induction; subsequent doses q12h (±4 hours window if nighttime)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the pain intensity-time curve (AUC0-48h) of resting pain NRS from 0 to 48 hours after surgeryTime frame: 0 to 48 hours after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Affiliated Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.